1 Min Read Why Does Immune Attack Sometimes Spiral Out of Control?
July 28, 2026Core Framework & Diagram Why Does Immune Attack Sometimes Spiral Out of Control?
July 28, 2026The immune system sometimes overshoots — and that can be more dangerous than the pathogen itself
—— Cytokine storms, autoimmune disease, allergy: when immune attack loses control.
I. 'Stronger immunity is better' — a dangerous misconception
'I need to boost my immunity' — this is one of the most common thoughts people have after getting sick, before getting sick, or after reading health articles.
But embedded in that thought is a dangerous logical flaw: the default assumption that immunity is 'the more the better.'
That's wrong. The ideal state of the immune system isn't 'as strong as possible' — it's 'precisely calibrated.' That means: responding rapidly and powerfully to real threats (pathogens, cancer cells), maintaining restraint and tolerance toward harmless substances (food proteins, pollen, self-tissue), and cleanly standing down once threats are cleared.
When each of these three conditions fails, a different immune over-activation disease results. First condition fails (response to threat too strong and can't stop) → cytokine storm, systemic inflammatory damage. Second condition fails (generates an attack response to harmless substances) → allergic reaction, from hay fever to anaphylaxis. Third condition fails (generates an attack response to self-tissue) → autoimmune disease, from type 1 diabetes to systemic lupus erythematosus.
Understanding these three types of immune over-activation clarifies why 'boosting immunity' is never an unconditionally worthwhile goal — and why the immune system's 'balance' matters far more than its 'strength.' This is one of the most important themes running through this entire series.
2. Cytokine storm: when inflammatory signals enter uncontrolled positive feedback
Cytokine storm isn't a metaphor — it has a precise definition: when pro-inflammatory cytokine secretion enters an uncontrolled positive feedback loop, more and more cytokines recruiting more and more immune cells, which secrete even more cytokines, ultimately exceeding what the host body can tolerate and causing serious damage to its own organs.
In normal immune responses, multiple negative feedback mechanisms prevent this runaway process: Treg cells secrete IL-10 to apply brakes; anti-inflammatory cytokines (IL-10, TGF-β) suppress pro-inflammatory signals; effector cells undergo apoptosis after threats are cleared; immune checkpoint molecules (PD-1, CTLA-4) prevent overactivation.
But in certain situations, these braking mechanisms can't function in time: when pathogen infection comes too fast and too intense, or when the pathogen itself interferes with regulatory mechanisms, or when the patient's immune regulatory capacity is impaired — pro-inflammatory signals spiral out of control.
The COVID-19 pandemic clearly revealed the clinical picture of cytokine storm. Blood tests from large numbers of severe patients showed extremely elevated levels of pro-inflammatory cytokines — IL-6, IL-1β, TNF-α, IFN-γ — and this elevation was directly linked to multi-organ damage (pulmonary ARDS, acute kidney injury, cardiac myocarditis). Viral infection's direct cellular damage, plus cytokine storm's systemic inflammatory harm, cooperated to cause COVID-19 severe cases.
The key clinical insight: for severe COVID-19, antiviral alone is insufficient — the uncontrolled immune response must also be simultaneously controlled. The combined use of tocilizumab (IL-6 receptor antagonist) and dexamethasone (broad-spectrum anti-inflammatory corticosteroid) significantly reduced severe COVID-19 mortality — direct validation of the 'antiviral + anti-immune-overactivation' dual approach.
3. Autoimmune disease: the immune system targeting its own tissue as the enemy
At the core of autoimmune disease is a failed 'friend-or-foe recognition' in the immune system — self-tissue that should be recognized as 'one of us' is treated as an attack target.
The roots of this recognition error were discussed in Articles 25 (Treg cells) and 16 (T cell training): central tolerance defects (thymus failing to delete self-reactive T cells) or peripheral tolerance dysregulation (Treg cell dysfunction unable to suppress escaped self-reactive T cells) allow T cells that should have been deleted to be activated in the periphery and attack self-tissue.
The diversity of autoimmune diseases is astonishing — they can affect almost any organ, depending on which self-antigens the self-reactive T cells and autoantibodies target: type 1 diabetes (attacks pancreatic beta cells → insulin secretion lost); rheumatoid arthritis (attacks joint synovium → chronic joint inflammation); systemic lupus erythematosus (attacks DNA/nuclear proteins → multi-organ involvement); multiple sclerosis (attacks neural myelin → demyelination); Hashimoto's thyroiditis (attacks thyroid → hypothyroidism).
Why are more and more people developing autoimmune diseases? Data from developed countries shows autoimmune disease incidence continuously rising over the past few decades. This has nothing to do with genetic factors (genetics don't change in a few decades) — and is highly correlated with declining gut microbiome diversity (loss of 'old friends' disrupting immune tolerance training), overly clean hygienic environments (reduced childhood infections affecting Treg development), exposure to certain environmental chemicals, and molecular mimicry from specific viral infections (viral protein sequences similar to self-proteins; post-infection antibodies may cross-attack self-tissue). Modern lifestyle's interference with immune regulation is an important driver of the autoimmune disease epidemic trend.
4. Allergy: an evolutionary anti-parasite weapon misfiring in modern life
Allergy — already discussed in detail in Articles 22 and 28 — is Th2-type responses incorrectly activated by harmless substances, excessive IgE production, mast cells and basophils being armed, producing over-reactive inflammatory responses to subsequent exposure to the same substance.
Three key points deserve re-emphasis to build a more complete understanding framework. First, allergy is a 'systemic error,' not a sign of 'weak immunity' — actually the opposite. Allergy typically reflects the immune system being too active in a specific direction (Th2 responses too strong). Many allergic people simultaneously have very strong infection response capacity. Understanding this avoids the trap of thinking 'I have allergies so I need to boost immunity,' which might actually worsen immune imbalance.
Second, the severity spectrum of allergy is very wide: from mild seasonal rhinitis, to asthma, to food allergy, to life-threatening anaphylaxis. These are immunologically the same process (IgE-mast cell/basophil), just with different sites, different allergen types, and different IgE concentrations producing dramatically different clinical presentations.
Third, understanding the immunological mechanism of allergy helps us understand the logic of existing treatments: antihistamines (block histamine receptors, control immediate symptoms), corticosteroids (broadly suppress inflammatory cascade, control late-phase reactions), epinephrine (reverse anaphylaxis hemodynamic collapse — the only first-line drug), anti-IgE monoclonal antibody omalizumab (blocks IgE binding to mast cells, lowering trigger sensitivity), and specific immunotherapy/desensitization (through long-term retraining, rebuilding tolerance to allergens). Not one treatment 'boosts immunity' — they all 'correct the immune system's overreaction' in different ways. This cognitive framework is the most important foundation for all allergy treatment decisions.
5. The immunotherapy paradox: the double-edged sword of releasing the brakes
The rise of tumor immunotherapy has brought an unprecedented clinical paradox: using 'releasing immune suppression' to treat cancer, while simultaneously inevitably inducing immune over-activation side effects in some patients.
PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab) block PD-1 receptors on T cells, releasing tumor microenvironment suppression of T cells and letting T cells reactivate to attack tumors. But PD-1 receptors are expressed not only on tumor-infiltrating T cells — T cells throughout the body are regulated by PD-1 signaling, including self-reactive T cells that were gently suppressed. PD-1 inhibitors release systemic T cell inhibition — while 'untying' tumor T cells, they simultaneously 'untie' self-reactive T cells, causing approximately fifteen to thirty percent of patients to develop immune-related adverse events (irAEs): dermatitis/rash, colitis (diarrhea), hepatitis (elevated transaminases), pneumonitis (interstitial pneumonia), endocrine inflammation (thyroiditis, hypophysitis) — essentially 'medically induced autoimmune diseases.'
Standard management of irAEs is to re-apply the brakes: mild irAEs, close observation; moderate to severe irAEs, pause immunotherapy and use glucocorticoids (prednisone) to suppress the overactivated immune response; severe irAEs may require permanent discontinuation and stronger immunosuppression (infliximab etc.).
This paradox — treating cancer requires releasing immune suppression, but releasing immune suppression induces autoimmunity — profoundly reflects the core importance of immune system 'balance.' We want T cells to attack tumors, but not to attack everything. Finding that precise middle state is one of the biggest clinical challenges in current tumor immunology — and the best example of why 'balance' always matters more than 'strength.'
Frequently Asked Questions